{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T23:19:14Z","timestamp":1769555954864,"version":"3.49.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1038\/s41409-020-0986-2","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T17:11:21Z","timestamp":1593191481000},"page":"110-120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8287-5673","authenticated-orcid":false,"given":"Jes\u00fas","family":"Duque-Afonso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8091-1589","authenticated-orcid":false,"given":"Gabriele","family":"Ihorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Waterhouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0813-3444","authenticated-orcid":false,"given":"Ralph","family":"W\u00e4sch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Bertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehtap","family":"Y\u00fccel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"M\u00fcller-Quernheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Marks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Finke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"986_CR1","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3324\/haematol.2015.132860","volume":"101","author":"R Storb","year":"2016","unstructured":"Storb R, Sandmaier BM. Nonmyeloablative allogeneic hematopoietic cell transplantation. Haematologica. 2016;101:521\u201330.","journal-title":"Haematologica"},{"key":"986_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","volume":"124","author":"B Gyurkocza","year":"2014","unstructured":"Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124:344\u201353.","journal-title":"Blood"},{"key":"986_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.7326\/0003-4819-104-2-163","volume":"104","author":"S Jagannath","year":"1986","unstructured":"Jagannath S, Dicke KA, Armitage JO, Cabanillas FF, Horwitz LJ, Vellekoop L, et al. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin\u2019s disease. Ann Intern Med. 1986;104:163\u20138.","journal-title":"Ann Intern Med"},{"key":"986_CR4","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/0277-5379(86)90376-7","volume":"22","author":"JO Armitage","year":"1986","unstructured":"Armitage JO, Jagannath S, Spitzer G, Bierman P, Kessinger A, Kumar P, et al. High dose therapy and autologous marrow transplantation as salvage treatment for patients with diffuse large cell lymphoma. Eur J Cancer Clin Oncol. 1986;22:871\u20137.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"986_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/bmt.2017.208","volume":"53","author":"D Sivaraj","year":"2018","unstructured":"Sivaraj D, Bacon W, Long GD, Rizzieri DA, Horwitz ME, Sullivan KM, et al. High-dose BCNU\/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma. Bone Marrow Transpl. 2018;53:34\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"986_CR6","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1212\/01.WNL.0000140495.33615.CA","volume":"63","author":"AA Brandes","year":"2004","unstructured":"Brandes AA, Tosoni A, Amist\u00e0 P, Nicolardi L, Grosso D, Berti F, et al. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology. 2004;63:1281\u20134.","journal-title":"Neurology"},{"key":"986_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1054-3589(08)60019-8","volume":"19","author":"RJ Weinkam","year":"1982","unstructured":"Weinkam RJ, Lin HS. Chloroethylnitrosourea cancer chemotherapeutic agents. Adv Pharm Chemother. 1982;19:1\u201333.","journal-title":"Adv Pharm Chemother"},{"key":"986_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/sj.bmt.1702154","volume":"25","author":"EP Alessandrino","year":"2000","unstructured":"Alessandrino EP, Bernasconi P, Colombo A, Caldera D, Martinelli G, Vitulo P, et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transpl. 2000;25:309\u201313.","journal-title":"Bone Marrow Transpl"},{"key":"986_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1056\/NEJM198007243030403","volume":"303","author":"PA Aronin","year":"1980","unstructured":"Aronin PA, Mahaley MS Jr, Rudnick SA, Dudka L, Donohue JF, Selker RG, et al. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors. N. Engl J Med. 1980;303:183\u20138.","journal-title":"N. Engl J Med"},{"key":"986_CR10","first-page":"1605","volume":"60","author":"NM Emanuel","year":"1976","unstructured":"Emanuel NM, Konovalova NP, Djachkovskaya RF. Toxicity, antitumor activity, and pharmacokinetics of spin-labeled thiotepa analogs. Cancer Treat Rep. 1976;60:1605\u20139.","journal-title":"Cancer Treat Rep"},{"key":"986_CR11","first-page":"736","volume":"49","author":"RL Heideman","year":"1989","unstructured":"Heideman RL, Cole DE, Balis F, Sato J, Reaman GH, Packer RJ, et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res. 1989;49:736\u201341.","journal-title":"Cancer Res"},{"key":"986_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ajh.24567","volume":"92","author":"S Eder","year":"2017","unstructured":"Eder S, Beohou E, Labopin M, Sanz J, Finke J, Arcese W, et al. Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia-A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2017;92:18\u201322.","journal-title":"Am J Hematol"},{"key":"986_CR13","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/ajh.24823","volume":"92","author":"S Eder","year":"2017","unstructured":"Eder S, Canaani J, Beohou E, Labopin M, Sanz J, Arcese W, et al. Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: a matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2017;92:997\u20131003.","journal-title":"Am J Hematol"},{"key":"986_CR14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/bmt.2016.239","volume":"52","author":"S Eder","year":"2017","unstructured":"Eder S, Labopin M, Finke J, Bunjes D, Olivieri A, Santarone S, et al. Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT. Bone Marrow Transpl. 2017;52:238\u201344.","journal-title":"Bone Marrow Transpl"},{"key":"986_CR15","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1200\/JCO.2006.06.2117","volume":"24","author":"G Illerhaus","year":"2006","unstructured":"Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006;24:3865\u201370.","journal-title":"J Clin Oncol"},{"key":"986_CR16","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3324\/haematol.2012.076075","volume":"98","author":"E Schorb","year":"2013","unstructured":"Schorb E, Kasenda B, Atta J, Kaun S, Morgner A, Hess G, et al. Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Haematologica. 2013;98:765\u201370.","journal-title":"Haematologica"},{"key":"986_CR17","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1046\/j.1365-2141.2000.02123.x","volume":"109","author":"AM Raiola","year":"2000","unstructured":"Raiola AM, Van Lint MT, Lamparelli T, Gualandi F, Mordini N, Berisso G, et al. Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. Br J Haematol. 2000;109:716\u201321.","journal-title":"Br J Haematol"},{"key":"986_CR18","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/sj.bmt.1702719","volume":"26","author":"T Lamparelli","year":"2000","unstructured":"Lamparelli T, van Lint MT, Gualandi F, Raiola AM, Barbanti M, Sacchi N, et al. Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin. Bone Marrow Transpl. 2000;26:1305\u201311.","journal-title":"Bone Marrow Transpl"},{"key":"986_CR19","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1200\/JCO.2003.09.110","volume":"21","author":"H Bertz","year":"2003","unstructured":"Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol. 2003;21:1480\u20134.","journal-title":"J Clin Oncol"},{"key":"986_CR20","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1182\/blood-2007-08-104745","volume":"112","author":"R Marks","year":"2008","unstructured":"Marks R, Potthoff K, Hahn J, Ihorst G, Bertz H, Spyridonidis A, et al. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. Blood. 2008;112:415\u201325.","journal-title":"Blood"},{"key":"986_CR21","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1038\/leu.2016.248","volume":"30","author":"H Bertz","year":"2016","unstructured":"Bertz H, L\u00fcbbert M, Ohneberg K, Zeiser R, W\u00e4sch R, Marks R, et al. Allogeneic hematopoietic cell transplantation with double alkylating agents containing reduced-intensity conditioning for patients \u2a7e60 years with advanced AML\/MDS. Leukemia. 2016;30:2426\u20139.","journal-title":"Leukemia"},{"key":"986_CR22","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.bbmt.2010.02.004","volume":"16","author":"B Deschler","year":"2010","unstructured":"Deschler B, Binek K, Ihorst G, Marks R, W\u00e4sch R, Bertz H, et al. Prognostic factor and quality of life analysis in 160 patients aged > or =60 years with hematologic neoplasias treated with allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2010;16:967\u201375.","journal-title":"Biol Blood Marrow Transpl"},{"key":"986_CR23","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41409-017-0021-4","volume":"53","author":"B Deschler","year":"2018","unstructured":"Deschler B, Ihorst G, Schnitzler S, Bertz H, Finke J. Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis. Bone Marrow Transpl. 2018;53:565\u201375.","journal-title":"Bone Marrow Transpl"},{"key":"986_CR24","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/bmt.2013.3","volume":"48","author":"J Duque-Afonso","year":"2013","unstructured":"Duque-Afonso J, Ihorst G, W\u00e4sch R, Bertz H, M\u00fcller-Quernheim J, Finke J, et al. Identification of risk factors for bronchiolitis obliterans syndrome after reduced toxicity conditioning before hematopoietic cell transplantation. Bone Marrow Transpl. 2013;48:1098\u2013103.","journal-title":"Bone Marrow Transpl"},{"key":"986_CR25","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1016\/j.bbmt.2018.06.024","volume":"24","author":"J Duque-Afonso","year":"2018","unstructured":"Duque-Afonso J, Ihorst G, Waterhouse M, Zeiser R, W\u00e4sch R, Bertz H, et al. Impact of lung function on bronchiolitis obliterans syndrome and outcome after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning. Biol Blood Marrow Transpl. 2018;24:2277\u201384.","journal-title":"Biol Blood Marrow Transpl"},{"key":"986_CR26","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/bmt.2015.273","volume":"51","author":"L Sellner","year":"2016","unstructured":"Sellner L, Boumendil A, Finel H, Choquet S, de Rosa G, Falzetti F, et al. EBMT Lymphoma Working Party. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. Bone Marrow Transpl. 2016;51:212\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"986_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/bmt.2017.205","volume":"53","author":"E Joffe","year":"2018","unstructured":"Joffe E, Rosenberg D, Rozovski U, Perry C, Kirgner I, Trestman S, et al. Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin\u2019s and non-Hodgkin\u2019s B-cell lymphoma. Bone Marrow Transpl. 2018;53:29\u201333.","journal-title":"Bone Marrow Transpl"},{"key":"986_CR28","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/bmt.2009.189","volume":"45","author":"SO Ciurea","year":"2010","unstructured":"Ciurea SO, Saliba R, Rondon G, Pesoa S, Cano P, Fernandez-Vina M, et al. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transpl. 2010;45:429\u201336.","journal-title":"Bone Marrow Transpl"},{"key":"986_CR29","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.clml.2013.08.006","volume":"14","author":"RS Mehta","year":"2014","unstructured":"Mehta RS, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, et al. The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. Clin Lymphoma Myeloma Leuk. 2014;14:e1\u20135.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"986_CR30","doi-asserted-by":"publisher","first-page":"e28030","DOI":"10.1002\/pbc.28030","volume":"67","author":"ST Bhatt","year":"2020","unstructured":"Bhatt ST, Schulz G, Hente M, Slater A, Murray L, Shenoy S, et al. A single-center experience using alemtuzumab, fludarabine, melphalan, and thiotepa as conditioning for transplantation in pediatric patients with chronic granulomatous disease. Pediatr Blood Cancer. 2020;67:e28030.","journal-title":"Pediatr Blood Cancer"},{"key":"986_CR31","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood"},{"key":"986_CR32","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/bmt.2011.110","volume":"47","author":"A Gratwohl","year":"2012","unstructured":"Gratwohl A. The EBMT risk score. Bone Marrow Transpl. 2012;47:749\u201356.","journal-title":"Bone Marrow Transpl"},{"key":"986_CR33","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.bbmt.2007.08.047","volume":"13","author":"E Copelan","year":"2007","unstructured":"Copelan E, Casper JT, Carter SL, van Burik JA, Hurd D, Mendizabal AM, et al. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transpl. 2007;13:1469\u201376.","journal-title":"Biol Blood Marrow Transpl"},{"key":"986_CR34","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","volume":"10","author":"J Finke","year":"2009","unstructured":"Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855\u201364.","journal-title":"Lancet Oncol"},{"key":"986_CR35","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1016\/S2352-3026(17)30081-9","volume":"4","author":"J Finke","year":"2017","unstructured":"Finke J, Schmoor C, Bethge WA, Ottinger H, Stelljes M, Volin L, et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematol. 2017;4:e293\u2013e301.","journal-title":"Lancet Haematol"},{"key":"986_CR36","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.bbmt.2009.08.002","volume":"15","author":"H Bertz","year":"2009","unstructured":"Bertz H, Spyridonidis A, W\u00e4sch R, Gr\u00fcllich C, Egger M, Finke J. A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation. Biol Blood Marrow Transpl. 2009;15:1563\u201370.","journal-title":"Biol Blood Marrow Transpl"},{"key":"986_CR37","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Acute Graft-versus-host disease - biologic process, prevention, and therapy. N. Engl J Med. 2017;377:2167\u201379.","journal-title":"N. Engl J Med"},{"key":"986_CR38","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N. Engl J Med. 2017;377:2565\u201379.","journal-title":"N. Engl J Med"},{"key":"986_CR39","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","volume":"18","author":"H Glucksberg","year":"1974","unstructured":"Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295\u2013304.","journal-title":"Transplantation"},{"key":"986_CR40","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1200\/JCO.1988.6.10.1562","volume":"6","author":"SI Bearman","year":"1988","unstructured":"Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6:1562\u20138.","journal-title":"J Clin Oncol"},{"key":"986_CR41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.clinbiochem.2017.11.015","volume":"52","author":"J Duque-Afonso","year":"2018","unstructured":"Duque-Afonso J, Waterhouse M, Pfeifer D, Follo M, Duyster J, Bertz H, et al. Cell-free DNA characteristics and chimerism analysis in patients after allogeneic cell transplantation. Clin Biochem. 2018;52:137\u201341.","journal-title":"Clin Biochem"},{"key":"986_CR42","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/sj.bmt.1701889","volume":"24","author":"D Behringer","year":"1999","unstructured":"Behringer D, Bertz H, Schmoor C, Berger C, Dwenger A, Finke J. Quantitative lymphocyte subset reconstitution after allogeneic hematopoietic transplantation from matched related donors with CD34+ selected PBPC grafts unselected PBPC grafts or BM grafts. Bone Marrow Transpl. 1999;24:295\u2013302.","journal-title":"Bone Marrow Transpl"},{"key":"986_CR43","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/cyto.990140703","volume":"14","author":"T Calvelli","year":"1993","unstructured":"Calvelli T, Denny TN, Paxton H, Gelman R, Kagan J. Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Immunologic Diseases, Division of AIDS. Cytometry. 1993;14:702\u201314.","journal-title":"Cytometry"},{"key":"986_CR44","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1164\/ajrccm.152.6.8520796","volume":"152","author":"American Thoracic Society.","year":"1995","unstructured":"American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique-1995 update. Am J Respir Crit Care Med. 1995;152:2185\u201398.","journal-title":"Am J Respir Crit Care Med"},{"key":"986_CR45","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1164\/rccm.201710-1981ST","volume":"196","author":"BH Culver","year":"2017","unstructured":"Culver BH, Graham BL, Coates AL, Wanger J, Berry CE, Clarke PK, et al. Recommendations for a Standardized Pulmonary Function Report. An Official American Thoracic Society Technical Statement. Am J Respir Crit Care Med. 2017;196:1463\u201372.","journal-title":"Am J Respir Crit Care Med"},{"key":"986_CR46","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/BF02718260","volume":"168","author":"AW Zaiss","year":"1990","unstructured":"Zaiss AW, Matthys H. A multi user system for whole body plethysmographic measurements and interpretation. Lung. 1990;168:1185\u201392.","journal-title":"Lung"},{"key":"986_CR47","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"J Fine","year":"1999","unstructured":"Fine J, Gray. R. A proportional hazards model for the subdistribution of a competing 25 risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"986_CR48","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1200\/JCO.2007.12.9866","volume":"26","author":"JJ Dignam","year":"2008","unstructured":"Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol. 2008;26:4027\u201334.","journal-title":"J Clin Oncol"},{"issue":"No. 2","key":"986_CR49","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2307\/2983604","volume":"1","author":"S Yates","year":"1934","unstructured":"Yates S. Contingency tables involving small numbers and the \u03c72 test. Suppl J R Stat Soc. 1934;1(No. 2):217\u201335. pp","journal-title":"Suppl J R Stat Soc"},{"key":"986_CR50","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/sj.bmt.1701103","volume":"21","author":"JD Down","year":"1998","unstructured":"Down JD, Westerhof GR, Boudewijn A, Setroikromo R, Ploemacher RE. Thiotepa improves allogeneic bone marrow engraftment without enhancing stem cell depletion in irradiated mice. Bone Marrow Transpl. 1998;21:327\u201330.","journal-title":"Bone Marrow Transpl"},{"key":"986_CR51","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.clml.2020.01.007","volume":"20","author":"J El-Cheikh","year":"2020","unstructured":"El-Cheikh J, Labopin M, Al-Chami F, Bazarbachi A, Angelucci E, Santarone S, et al. Effect of the Thiotepa Dose in the TBF conditioning regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia in complete remission: a report from the EBMT acute leukemia working party. Clin Lymphoma Myeloma Leuk. 2020;20:296\u2013304.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"986_CR52","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1164\/rccm.201709-1845OC","volume":"197","author":"S Kafaja","year":"2018","unstructured":"Kafaja S, Clements PJ, Wilhalme H, Tseng CH, Furst DE, Kim GH, et al. Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II). Am J Respir Crit Care Med. 2018;197:644\u201352.","journal-title":"Am J Respir Crit Care Med"},{"key":"986_CR53","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transpl. 2009;15:367\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"986_CR54","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1182\/bloodadvances.2018021980","volume":"2","author":"M Eapen","year":"2018","unstructured":"Eapen M, Brazauskas R, Hemmer M, Perez WS, Steinert P, Horowitz MM, et al. Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. Blood Adv. 2018;2:2095\u2013103.","journal-title":"Blood Adv"},{"key":"986_CR55","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","volume":"130","author":"L Muffly","year":"2017","unstructured":"Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017;130:1156\u201364.","journal-title":"Blood"},{"key":"986_CR56","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","volume":"35","author":"BL Scott","year":"2017","unstructured":"Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35:1154\u201361.","journal-title":"J Clin Oncol"},{"key":"986_CR57","doi-asserted-by":"publisher","unstructured":"Scott BL. Long-term follow up of BMT CTN 0901, a randomized phase III trial comparing myeloablative (MAC) to reduced intensity conditioning (RIC) prior to hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) or myelodysplasia (MDS) (MAvRIC Trial). Biol Blood Marrow Transpl. 2020. https:\/\/doi.org\/10.1016\/j.bbmt.2019.12.075.","DOI":"10.1016\/j.bbmt.2019.12.075"},{"key":"986_CR58","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"AJM Ferreri","year":"2017","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Ros\u00e9e P, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4:e510\u2013e523.","journal-title":"Lancet Haematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-0986-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-0986-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-0986-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:18:30Z","timestamp":1744150710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-0986-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["986"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-0986-2","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,26]]},"assertion":[{"value":"8 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicting financial interest with the submission of this article. JF received research support and speakers honoraria from Medac, Neovii and Riemser. JD-A received speakers honoraria from Roche and travel support from Gilead and Sobi. RZ received speakers honoraria from Incyte, Novartis, Roche, and Mallinckroth.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}